A Phase III Study of SHR-A2102 Versus Investigator-selected Therapy in Advanced Urothelial Carcinoma

NCT06738251 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

402

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Urothelial Carcinoma

Interventions

DRUG: SHR-A2102 for Injection
DRUG: Docetaxel Injection
DRUG: Paclitaxel Injection
DRUG: Gemcitabine Hydrochloride for Injection
DRUG: Pemetrexed Disodium for Injection

Sponsor

Shanghai Hengrui Pharmaceutical Co., Ltd.